Fetal cardiac safety of sertraline use during pregnancy

References

• Kolding L, Ehrenstein V, Pedersen L, et al. Antidepressant use in pregnancy and severe cardiac malformations: danish register-based study. BJOG. 2021 Nov;128(12):1949–1957.
   PubMed Web of Science ®Google Scholar
• Kolding L, Eken H, Uldbjerg N. Drug exposure during pregnancy and fetal cardiac function - a systematic review. J Perinat Med. 2020 Mar 26;48(3):199–208. doi: 10.1515/jpm-2019-0402
   PubMed Web of Science ®Google Scholar
• Lash TL, Vanderweele TJ, Haneuse S, et al. Modern epidemiology. Philadelphia, PA, USA: Wolters Kluwer; 2021.
   Google Scholar
• Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675–2683. doi: 10.1056/NEJMoa067407
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339(sep23 1):b3569. doi: 10.1136/bmj.b3569
   PubMedGoogle Scholar
• Amrhein V, Greenland S, McShane BB. Statistical significance gives bias a free pass. Eur J Clin Invest. 2019 Dec;49(12):e13176. doi: 10.1111/eci.13176
   PubMed Web of Science ®Google Scholar
• Sedgwick PM, Hammer A, Kesmodel US, et al. Current controversies: null hypothesis significance testing. Acta Obstet Gynecol Scand. 2022;101(6):624–627. doi: 10.1111/aogs.14366
   PubMed Web of Science ®Google Scholar
• Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiatry. 2020 Dec 1;77(12):1246–1255. doi: 10.1001/jamapsychiatry.2020.2453
   PubMed Web of Science ®Google Scholar
• Gao SY, Wu QJ, Sun C, et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018 Nov 12;16(1):205. doi: 10.1186/s12916-018-1193-5
   PubMedGoogle Scholar
• Hong F, Qiu J, Zhang S, et al. Fetal congenital cardiac and vascular disorders associated with sertraline treatment during pregnancy: analysis of FAERS data. Bio Med Res Int. 2022;2022:1–11. doi: 10.1155/2022/9914931
   Google Scholar
• Huybrechts KF, Hernández-Díaz S, Avorn J. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014 Sep 18;371(12):1168–1169. doi: 10.1056/NEJMc1409203
   PubMedGoogle Scholar
• De Vries C, Gadzhanova S, Sykes MJ, et al. A systematic review and meta-analysis considering the risk for congenital heart defects of antidepressant classes and individual antidepressants. Drug Saf. 2021 Mar;44(3):291–312.
   PubMed Web of Science ®Google Scholar
• Kolding L, Ehrenstein V, Pedersen L, et al. Antidepressant use in pregnancy and severe cardiac malformations: danish register‐based study. BJOG: An Int J Obstetrics & Gynaecol. 2021;128(12):1949–1957. doi: 10.1111/1471-0528.16772
   PubMed Web of Science ®Google Scholar
• Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG: Int J Obstet Gy. 2014 Nov;121(12):1471–1481.
   PubMed Web of Science ®Google Scholar
• Berard A, Sheehy O, Croy A. The Quebec pregnancy cohort – prevalence of medication use during gestation and pregnancy outcomes. PLoS One. 2014;9(4):e93870. doi: 10.1371/journal.pone.0093870
   PubMed Web of Science ®Google Scholar
• Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015 Apr 17;350(apr17 3):h1798. doi: 10.1136/bmj.h1798
   PubMedGoogle Scholar
• Jordan S, Morris JK, Davies GI, et al. Selective serotonin reuptake inhibitor (ssri) antidepressants in pregnancy and congenital anomalies: analysis of linked databases in Wales, Norway and Funen, Denmark. PLoS One. 2016;11(12):e0165122. doi: 10.1371/journal.pone.0165122
   PubMed Web of Science ®Google Scholar
• Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res Part A, Clin Mol Teratol. 2009 Oct;85(10):837–841.
   PubMedGoogle Scholar
• Nordeng H, van Gelder MM, Spigset O, et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. J Clin Psychopharmacol. 2012 Apr;32(2):186–194. doi: 10.1097/JCP.0b013e3182490eaf
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects ResB DevReprodtoxicol. 2008;83(1):68–76. doi: 10.1002/bdrb.20144
   PubMedGoogle Scholar
• Haskell SE, Lo C, Kent ME, et al. Cardiac outcomes after perinatal sertraline exposure in mice. J Cardiovasc Pharmacol. 2017 Aug;70(2):119–127.
   PubMed Web of Science ®Google Scholar
• Haskell SE, Hermann GM, Reinking BE, et al. Sertraline exposure leads to small left heart syndrome in adult mice. Pediatr Res. 2013 Mar;73(3):286–293.
   PubMed Web of Science ®Google Scholar
• Kent ME, Hu B, Eggleston TM, et al. Hypersensitivity of zebrafish htr2b mutant embryos to sertraline indicates a role for serotonin signaling in cardiac development. J Cardiovasc Pharmacol. 2022 Aug 1;80(2):261–269. doi: 10.1097/FJC.0000000000001297
   PubMed Web of Science ®Google Scholar
• Kolding L, Pedersen LH, Petersen OB, et al. Sertraline use during pregnancy and effect on fetal cardiac function. J Matern-Fetal Neonatal Med. 2021 Nov;34(22):3631–3638. doi: 10.1080/14767058.2019.1688297
   PubMed Web of Science ®Google Scholar
• Ansah DA, Reinking BE, Colaizy TT, et al. A prospective study evaluating the effects of ssri exposure on cardiac size and function in newborns. Neonatology. 2019;115(4):320–327. doi: 10.1159/000496451
   PubMed Web of Science ®Google Scholar
• Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994 Jan 12;271(2):146–150. doi: 10.1001/jama.1994.03510260078033
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Petersen OB, Nørgaard M, et al. Linkage between the danish national health service prescription database, the Danish Fetal Medicine Database, and other Danish registries as a tool for the study of drug safety in pregnancy. Clin Epidemiol. 2016;8:91. doi: 10.2147/CLEP.S98139
   PubMed Web of Science ®Google Scholar
• Thunbo MØ, Vendelbo JH, Volqvartz T, et al. Polypharmacy in polymorbid pregnancies and the risk of congenital malformations—A systematic review. Basic Clin Pharmacol Toxicol. 2022;130(3):394–414. Figure. Meta-analysis excluding the case-control study Andersons et al 2020. doi: 10.1111/bcpt.13695
   PubMed Web of Science ®Google Scholar